Viewing Study NCT04320602

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2026-05-27 @ 10:52 AM
Study NCT ID: NCT04320602
Status: COMPLETED
Last Update Posted: 2024-09-05
First Post: 2020-03-23
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
Sponsor: Alexion Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Paroxysmal Nocturnal Hemoglobinuria View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Paroxysmal Nocturnal Hemoglobinuria View
None PNH View
None Ravulizumab View
None Ultomiris View
None Eculizumab View
None Soliris View